Skip to main content
SMFM 2025 Pregnancy Meeting Main banner
Final Program


Program Book
Icon Legend
Presentation Icons
Additional registration fee required
Additional registration fee required
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording
Recording
Poster Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared on social media
Faculty have requested this content not be shared on social media
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Back

Poster Session 2

(520) Association of Isolated Leukocytosis in Early Pregnancy with Adverse Pregnancy Outcomes

Thursday, January 30, 2025
4:00 PM – 6:00 PM  

    Submitting Author and Presenting Author(s)

  • Ji Yeon Lee, MD, PhD (she/her/hers)

    Associate Professor
    Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine
    Seongnam, Kyonggi-do, Republic of Korea

    • Coauthor(s)

  • Nari Kim, MD

    Clinical Fellow
    Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine
    CHA Bundang Medical Center, CHA University School of Medicine / Seongnam, Kyonggi-do, Republic of Korea

  • YK

    Yeomin E. Kang

    University of Maryland
    Baltimore, Maryland, United States

Objective:

Animal studies suggest that maternal systemic inflammation in early pregnancy can affect adverse outcomes. There is no clear standard for maternal leukocytosis, and there is limited research on how high white blood cell(WBC) counts affect outcomes. This study aims to investigate how high WBC counts in the first trimester relate to adverse pregnancy outcomes and identify the WBC count level linked to poor prognosis.

Study Design:

This retrospective cohort study included healthy, singleton pregnant women who delivered between 2014 and 2023. Cases included only those without fetal anomalies and no fever at the time of the first trimester laboratory test. Women showing signs of infection/inflammation or with autoimmune diseases were excluded. Women with a WBC count of 13,000-14,000 in the first trimester were classified as group I (n=382), those with a WBC count of 14,000-15,000 as group II (n=151), and those with a WBC count of ≥15,000 as group III (n=70). Meanwhile, those with a WBC count of 7,500-8,500 were designated as the control group (n=1,524). Multivariate analysis was performed considering maternal characteristics.

Results:

Groups I/II did not show statistical differences in adverse outcomes compared to the control group. However, group III had significantly higher risks compared to the control group, including the risk of preterm birth(PTB) before 32 weeks (aOR 5.5, 95% CI 1.5-20.6, P=0.012), before 34 weeks (aOR 8.2, 95%CI 3.4-20.3, P< 0.001), and before 36 weeks (aOR 2.9, 95%CI 1.4-6.1, P=0.006). Additionally, the risks of gestational diabetes(GDM) (aOR 2.1, 95%CI 1.2-3.7, P=0.013), cesarean delivery(CD) (aOR 1.8, 95%CI 1.1-3.1, P=0.029), transient tachypnea(TTN) (aOR 2.6, 95%CI 1.1-6.3, P=0.036), and neonatal jaundice (aOR 1.7, 95%CI 1.1-2.8, P=0.039) were also elevated in group III compared to the control group.

Conclusion:

Associations between high WBC counts (≥15,000) in early pregnancy and increased risks of PTB, GDM, CD, TTN, and neonatal jaundice have been observed. High first-trimester WBC counts may help predict adverse pregnancy outcomes.